358 related articles for article (PubMed ID: 28828496)
1. Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.
Haderlein M; Scherl C; Semrau S; Lettmaier S; Hecht M; Erber R; Iro H; Fietkau R; Agaimy A
Strahlenther Onkol; 2017 Nov; 193(11):961-970. PubMed ID: 28828496
[TBL] [Abstract][Full Text] [Related]
2. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.
Boon E; Bel M; van Boxtel W; van der Graaf WTA; van Es RJJ; Eerenstein SEJ; Baatenburg de Jong RJ; van den Brekel MWM; van der Velden LA; Witjes MJH; Hoeben A; Willems SM; Bloemena E; Smit LA; Oosting SF; ; Jonker MA; Flucke UE; van Herpen CML
Int J Cancer; 2018 Aug; 143(4):758-766. PubMed ID: 29492965
[TBL] [Abstract][Full Text] [Related]
3. A 20-Year Review of 75 Cases of Salivary Duct Carcinoma.
Gilbert MR; Sharma A; Schmitt NC; Johnson JT; Ferris RL; Duvvuri U; Kim S
JAMA Otolaryngol Head Neck Surg; 2016 May; 142(5):489-95. PubMed ID: 26939990
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.
Masubuchi T; Tada Y; Maruya S; Osamura Y; Kamata SE; Miura K; Fushimi C; Takahashi H; Kawakita D; Kishimoto S; Nagao T
Int J Clin Oncol; 2015 Feb; 20(1):35-44. PubMed ID: 24553861
[TBL] [Abstract][Full Text] [Related]
5. Parotid salivary duct carcinoma: a single institution's 20-year experience.
Stodulski D; Mikaszewski B; Majewska H; Kuczkowski J
Eur Arch Otorhinolaryngol; 2019 Jul; 276(7):2031-2038. PubMed ID: 31062093
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and outcome analysis of salivary duct carcinoma.
Han MW; Roh JL; Choi SH; Nam SY; Lee HJ; Cho KJ; Lee SW; Kim SY
Auris Nasus Larynx; 2015 Dec; 42(6):472-7. PubMed ID: 26028371
[TBL] [Abstract][Full Text] [Related]
7. [Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma].
Otsuka K; Imanishi Y; Habu N; Sato Y; Shigetomi S; Fujii R; Sakamoto K; Tomita T; Fujii M; Kameyama K; Ogawa K
Nihon Jibiinkoka Gakkai Kaiho; 2013 Sep; 116(9):1024-32. PubMed ID: 24191589
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features and treatment outcomes of the rare, salivary duct carcinoma of parotid gland.
Al-Qahtani KH; Tunio MA; Bayoumi Y; Gurusamy VM; Bahamdain FA; Fatani H
J Otolaryngol Head Neck Surg; 2016 May; 45(1):32. PubMed ID: 27184361
[TBL] [Abstract][Full Text] [Related]
9. Salivary duct carcinoma.
D'heygere E; Meulemans J; Vander Poorten V
Curr Opin Otolaryngol Head Neck Surg; 2018 Apr; 26(2):142-151. PubMed ID: 29373327
[TBL] [Abstract][Full Text] [Related]
10. Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database.
Jayaprakash V; Merzianu M; Warren GW; Arshad H; Hicks WL; Rigual NR; Sullivan MA; Seshadri M; Marshall JR; Cohan DM; Zhao Y; Singh AK
Head Neck; 2014 May; 36(5):694-701. PubMed ID: 23606370
[TBL] [Abstract][Full Text] [Related]
11. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance.
Nagao T; Gaffey TA; Visscher DW; Kay PA; Minato H; Serizawa H; Lewis JE
Am J Surg Pathol; 2004 Mar; 28(3):319-26. PubMed ID: 15104294
[TBL] [Abstract][Full Text] [Related]
12. Salivary gland carcinoma (SGC) with perineural spread and/or positive resection margin - high locoregional control rates after photon (chemo) radiotherapy - experience from a monocentric analysis.
Haderlein M; Scherl C; Semrau S; Lettmaier S; Hecht M; Putz F; Iro H; Agaimy A; Fietkau R
Radiat Oncol; 2019 Apr; 14(1):68. PubMed ID: 31014362
[TBL] [Abstract][Full Text] [Related]
13. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.
Jaehne M; Roeser K; Jaekel T; Schepers JD; Albert N; Löning T
Cancer; 2005 Jun; 103(12):2526-33. PubMed ID: 15900577
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients.
Williams MD; Roberts D; Blumenschein GR; Temam S; Kies MS; Rosenthal DI; Weber RS; El-Naggar AK
Am J Surg Pathol; 2007 Nov; 31(11):1645-52. PubMed ID: 18059220
[TBL] [Abstract][Full Text] [Related]
15. Cervical Lymph Node Metastatic Status and Adjuvant Therapy Predict the Prognosis of Salivary Duct Carcinoma.
Qian K; Di L; Guo K; Zheng X; Ji Q; Wang Z
J Oral Maxillofac Surg; 2018 Jul; 76(7):1578-1586. PubMed ID: 29544756
[TBL] [Abstract][Full Text] [Related]
16. The role of postoperative radiation therapy in carcinoma ex pleomorphic adenoma of the parotid gland.
Chen AM; Garcia J; Bucci MK; Quivey JM; Eisele DW
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):138-43. PubMed ID: 17049183
[TBL] [Abstract][Full Text] [Related]
17. Carcinoma ex pleomorphic adenoma: a clinicopathologic review.
Olsen KD; Lewis JE
Head Neck; 2001 Sep; 23(9):705-12. PubMed ID: 11505478
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor immunoexpression evaluation in malignant salivary gland tumours.
Monteiro LS; Bento MJ; Palmeira C; Lopes C
J Oral Pathol Med; 2009 Jul; 38(6):508-13. PubMed ID: 19317849
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of lymph node density in high-grade salivary gland cancers.
Hong HR; Roh JL; Cho KJ; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2015 May; 111(6):784-9. PubMed ID: 25640975
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas.
Ettl T; Schwarz S; Kleinsasser N; Hartmann A; Reichert TE; Driemel O
Histopathology; 2008 Nov; 53(5):567-77. PubMed ID: 18983466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
